Disposition of cannabinoids in oral fluid after controlled around-the-clock oral THC administration

Clinical Chemistry

Volumn 56, Issue 8, 2010, Pages 1261-1269

  Milman, Garry ^a   Barnes, Allan J ^a   Schwope, David M ^a   Schwilke, Eugene W ^a,b   Darwin, William D ^a   Goodwin, Robert S ^a   Kelly, Deanna L ^c   Gorelick, David A ^a   Huestis, Marilyn A ^a  

^a NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

^b AIT Laboratories   (United States)

^c UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANNABIDIOL; CANNABINOID DERIVATIVE; CANNABINOL; DRONABINOL; SOLVENT;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL LABORATORY; CONTROLLED STUDY; DRUG DISPOSITION; DRUG MONITORING; ELUTION; FEMALE; FLUID THERAPY; FORENSIC SCIENCE; GAS CHROMATOGRAPHY; HUMAN; IONIZATION; MALE; MASS SPECTROMETRY; QUANTITATIVE ANALYSIS;

ADOLESCENT; ADULT; HUMANS; MALE; MARIJUANA ABUSE; SALIVA; SUBSTANCE ABUSE DETECTION; TETRAHYDROCANNABINOL; TIME FACTORS; YOUNG ADULT;

CANNABIS;

EID: 77955238250     PISSN: 00099147     EISSN: 15308561     Source Type: Journal    
DOI: 10.1373/clinchem.2009.141853     Document Type: Article

References (33)

1. Verstraete AG. Oral fluid testing for driving under the influence of drugs: history, recent progress and remaining challenges. Forensic Sci Int 2005; 150:143-50.
2. Bosker WM, Huestis MA. Oral fluid testing for drugs of abuse. Clin Chem 2009;55:1910-31.
3. Halldin MM, Widman M, Bahr CV, Lindgren JE, Martin BR. Identification of in vitro metabolites of delta-tetrahydrocannabinol formed by human livers. Drug Metab Dispos 1982;10:297-301. (Pubitemid 12049195)
4. 9-tetrahydrocannabinol, cannabidiol and cannabinol. In: Pertwee RG, ed. Cannabinoids. New York: Springer; 2005. p 657-90. Handbook of experimental pharmacology, vol. 168.
5. Harvey DJ, Paton WDM. Metabolism of the cannabinoids. Rev Biochem Toxicol 1986;6:221-64.
6. Perez-Reyes M, Di Guiseppi S, Davis KH, Schindler VH, Cook CE. Comparison of effects of marijuana cigarettes of three different potencies. Clin Pharmacol Ther 1982;31:617-24. (Pubitemid 13105521)
7. Huestis MA, Cone EJ. Relationship of delta 9-tetrahydrocannabinol concentrations in oral fluid and plasma after controlled administration of smoked cannabis. J Anal Toxicol 2004;28: 394-9.
8. Kauert GF, Ramaekers JG, Schneider E, Moeller MR, Toennes SW. Pharmacokinetic properties of delta9-tetrahydrocannabinol in serum and oral fluid. J Anal Toxicol 2007;31:288-93. (Pubitemid 46911627)
9. Cone EJ, Huestis MA. Interpretation of oral fluid tests for drugs of abuse. Ann N Y Acad Sci 2007;1098:51-103. (Pubitemid 47092558)
10. Moore C, Rana S, Coulter C. Simultaneous identification of 2-carboxy-tetrahydrocannabinol, tetrahydrocannabinol, cannabinol and cannabidiol in oral fluid. J Chrom B-Anal Tech Biomed Life Sci 2007;852:459-64. (Pubitemid 46830152)
11. Perez-Reyes M. Marijuana smoking: factors that influence the bioavailability of tetrahydrocannabinol. In: Chiang CN, Hawks RL, eds. Research findings on smoking of abused substances. Rockville (MD): National Institute on Drug Abuse; 1990. p 42-62. NIDA research monograph nr 99.
12. Kintz P, Cirimele V, Ludes B. Detection of cannabis in oral fluid (saliva) and forehead wipes (sweat) from impaired drivers. J Anal Toxicol 2000;24:557-61.
13. Huestis MA, Cone EJ. Alternative testing matrices. In: Karch SB, ed. Drug abuse handbook. Boca Raton, FL: CRC Press, 1998:799-857.
14. Moore C, Coulter C, Rana S, Vincent M, Soares J. Analytical procedure for the determination of the marijuana metabolite 11-nor-delta9- tetrahydrocannabinol-9-carboxylic acid in oral fluid specimens. J Anal Toxicol 2006;30:409-12. (Pubitemid 44371480)
15. Day D, Kuntz DJ, Feldman M, Presley L. Detection of THCA in oral fluid by GC-MS-MS. J Anal Toxicol 2006;30:645-50. (Pubitemid 44913015)
16. Huestis MA, Elsohly M, Nebro W, Barnes A, Gustafson RA, Smith ML. Estimating time of last oral ingestion of cannabis from plasma THC and THCCOOH concentrations. Ther Drug Monit 2006; 28:540-4. (Pubitemid 44181488)
17. Cone EJ, Johnson RE, Paul BD, Mell LD, Mitchell J. Marijuana-laced brownies: behavioral effects, physiologic effects, and urinalysis in humans following ingestion. J Anal Toxicol 1988;12:169-75.
18. Leson G, Pless P, Grotenhermen F, Kalant H, ElSohly MA. Evaluating the impact of hemp food consumption on workplace drug tests. J Anal Toxicol 2001;25:691-8. (Pubitemid 33095889)
19. Ben Amar M. Cannabinoids in medicine: a review of their therapeutic potential. J Ethnopharmacol 2006;105:1-25.
20. Lemberger L, Weiss JL, Watanabe AM, Galanter LM, Wyatt RJ, Cardon PV. Delta-9-tetrahydrocannabinol temporal correlation of the psychologic effects and blood levels after various routes of administration. N Engl J Med 1972;286:685-8.
21. Wall ME, Sadler BM, Brine D, Taylor H, Perez-Reyes M. Metabolism, disposition, and kinetics of delta-9-tetrahydrocannabinol in men and women. Clin Pharmacol Ther 1983;34:352-63. (Pubitemid 13006304)
22. Sporkert F, Pragst F, Ploner CJ, Tschirch A, Stadelmann AM. Pharmacokinetic investigations and delta-9-tetrahydrocannabinol and its metabolites after single administration of 10 mg Marinol in attendance of a psychiatric study [Poster]. From: Annual meeting of The International Association of Forensic Toxicologists; 2001 Aug 26-30; Prague, Czech Republic. P62.
23. Ohlsson A, Lindgren JE, Wahlen A, Agurell S, Hollister LE, Gillespie HK. Plasma delta-9-tetrahydrocannabinol concentrations and clinical effects after oral and intravenous administration and smoking. Clin Pharmacol Ther 1980;28:409-16. (Pubitemid 10007024)
24. Brenneisen R, Egli A, ElSohly MA, Henn V, Spiess Y. The effect of orally and rectally administered delta-9-tetrahydrocannabinol on spasticity: a pilot study with 2 patients. Int J Clin Pharmacol Ther 1996;34:446-52. (Pubitemid 26341135)
25. Goodwin RS, Gustafson RA, Barnes A, Nebro W, Moolchan ET, Huestis MA. Delta(9)-tetrahydrocannabinol, 11-hydroxy-delta(9)-tetrahydrocannabinol and 11-nor-9-carboxy-delta(9)-tetrahydrocannabinol in human plasma after controlled oral administration of cannabinoids. Ther Drug Monit 2006;28:545-51.
26. Schwilke EW, Schwope DM, Karschner EL, Lowe RH, Darwin WD, Kelly DL, et al. Delta9-tetrahydrocannabinol (THC), 11-hydroxy-THC, and 11-nor-9-carboxy-THC plasma pharmacokinetics during and after continuous high-dose oral THC. Clin Chem 2009;55:2180-9.
27. Milman G, Barnes AJ, Lowe RH, Huestis MA. Simultaneous quantification of cannabinoids and metabolites in oral fluid by two-dimensional gas chromatography mass spectrometry. J Chrom A 2010;1217:1513-21.
28. Haney M, Ward AS, Comer SD, Foltin RW, Fischman MW. Abstinence symptoms following oral THC administration to humans. Psychopharmacology 1999;141:385-94. (Pubitemid 29190007)
29. Quintela O, Crouch DJ, Andrenyak DM. Recovery of drugs of abuse from the Immunalysis Quantisal oral fluid collection device. J Anal Toxicol 2006; 30:614-6. (Pubitemid 44600855)
30. Moore C, Ross W, Coulter C, Adams L, Rana S, Vincent M, et al. Detection of the marijuana metabolite 11-nor-delta9-tetrahydrocannabinol-9-carboxylic acid in oral fluid specimens and its contribution to positive results in screening assays. J Anal Toxicol 2006;30:413-8. (Pubitemid 44371481)
31. Johansson E, Halldin MM, Agurell S, Hollister LE, Gillespie HK. Terminal elimination plasma halflife of delta-1-tetrahydrocannabinol (delta-1-THC) in heavy users of marijuana. Eur J Clin Pharmacol 1989;37:273-7. (Pubitemid 19242734)
32. Moore C, Rana S, Coulter C, Day D, Vincent M, Soares J. Detection of conjugated 11-nor-delta9-tetrahydrocannabinol-9-carboxylic acid in oral fluid. J Anal Toxicol 2007;31:187-94. (Pubitemid 46708658)
33. DHHS. Mandatory guidelines for federal workplace drug testing. Fed Regist 2008;73:71858-907.